Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE

This article was originally published in The Tan Sheet

Executive Summary

ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE would be needed to support an Rx-to-OTC switch application, Nonprescription Drugs Advisory Committee Chairman Randy Juhl, PhD, University of Pittsburgh, concluded during a joint meeting of NDAC and the Pulmonary-Allergy Drugs Advisory Committee on Nov. 14. "I think the questions" raised during committee discussion of OTC marketing of asthma drugs "more revolve around the natural course of asthma than about the drug itself," Juhl commented. "I think those questions at this point are not overcomeable just by the drug itself. We really need to know more about asthma."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel